Yalcin, A. Et Al. 2011. Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions. 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (İstanbul, Turkey), 366.

Yalcin, A., Bisgin, A., ÇETİNKAYA, R., & GÜMÜŞLÜ, S., (2011). Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions . 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.366). İstanbul, Turkey

Yalcin, A. Et Al. "Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions," 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), İstanbul, Turkey, 2011

Yalcin, A. Et Al. "Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions." 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , İstanbul, Turkey, pp.366, 2011

Yalcin, A. Et Al. (2011) . "Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions." 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , İstanbul, Turkey, p.366.

@conferencepaper{conferencepaper, author={A. Yalcin Et Al. }, title={Clinical efficacy of omalizumab in severe persistent asthma and co-morbid conditions}, congress name={30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={İstanbul}, country={Turkey}, year={2011}, pages={366} }